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Myocardin-Related Transcription Factors A and B
Are Key Regulators of TGF-b1-Induced Fibroblast
to Myofibroblast Differentiation
Beverly J. Crider1, George M. Risinger1 Jr, Carol J. Haaksma1, Eric W. Howard1 and James J. Tomasek1
Myofibroblasts are contractile, smooth muscle-like cells that are characterized by the de novo expression of
smooth muscle a-actin (SMaA) and normally function to assist in wound closure, but have been implicated in
pathological contractures. Transforming growth factor b-1 (TGF-b1) helps facilitate the differentiation of
fibroblasts into myofibroblasts, but the exact mechanism by which this differentiation occurs, in response to
TGF-b1, remains unclear. Myocardin-related transcription factors A and B (MRTFs, MRTF-A/B) are transcriptional
co-activators that regulate the expression of smooth muscle-specific cytoskeletal proteins, including SMaA, in
smooth muscle cells and fibroblasts. In this study, we demonstrate that TGF-b1 mediates myofibroblast
differentiation and the expression of a contractile gene program through the actions of the MRTFs. Transient
transfection of a constitutively active MRTF-A induced an increase in the expression of SMaA and other smooth
muscle-specific cytoskeletal proteins, and an increase in myofibroblast contractility, even in the absence of
TGF-b1. MRTF-A/B knockdown, in TGF-b1-differentiated myofibroblasts, resulted in decreased smooth muscle-
specific cytoskeletal protein expression levels and reduced contractile force generation, as well as a decrease in
focal adhesion size and number. These results provide direct evidence that the MRTFs are mediators of
myofibroblast differentiation in response to TGF-b1.
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INTRODUCTION
Myofibroblasts are specialized contractile fibroblasts that are
critical in generating the contractile force responsible for wound
closure and pathological contractures (Gabbiani et al., 1971;
Ryan et al., 1974; Gabbiani, 1981; Desmouliere and Gabbiani,
1995). These cells are characterized by the acquisition of a
contractile phenotype, which includes the formation of large
stress fibers and supermature focal adhesions, and expression of
smooth muscle a-actin (SMaA; Darby et al., 1990; Serini and
Gabbiani, 1999; Dugina et al., 2001), all of which are correlated
with generation of contractile force (Hinz et al., 2001, 2002).
Transforming growth factor-b 1 (TGF-b1) can promote the
differentiation of fibroblasts into myofibroblasts, both in vivo and
in vitro (Desmouliere et al., 1993; Tomasek et al., 2002);
however, the exact mechanism by which this occurs remains
unclear. An understanding of the regulation of myofibroblast
formation and function will be important in controlling wound
healing and pathological contractures. A major goal of our
laboratory has been to elucidate control processes that regulate
myofibroblast differentiation by identifying mechanisms that
control acquisition of the contractile phenotype and expression
of SMaA and other contractile cytoskeletal proteins.
Our laboratory has previously demonstrated that the
intronic CArG box element (CC[A/T]6GG) in the SMaA gene
regulates its expression in myofibroblasts in granulation tissue
(Tomasek et al., 2005). Other smooth muscle-specific
cytoskeletal proteins contain CArG box DNA-response
elements in the promoter regions of their genes, and their
regulation is mediated by the activity of serum response
factor (SRF) and its two cofactors, myocardin-related tran-
scription factors A and B (MRTFs; Wang et al., 2002; Cen
et al., 2003; Chambers et al., 2003; Sun et al., 2006; Descot
et al., 2009). Overexpressing the MRTFs in fibroblasts
increases the expression of CArG box-containing contractile
genes such as SMaA and caldesmon (Morita et al., 2007b).
Conversely, knockdown of the MRTFs or overexpression of
dominant-negative MRTF-A, in fibroblasts, results in de-
creased expression of contractile genes and the presence of
stress fibers and focal adhesions (Morita et al., 2007b; Chan
et al., 2010). In addition, MRTF-A-null mice have reduced
fibrosis and SMaA expression in a myocardial infarction
model of myofibroblast differentiation (Small et al., 2010).
These results implicate MRTFs as potential key regulators of
myofibroblast formation and function.
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The transcriptional activity of MRTFs is regulated by actin
dynamics (Miralles et al., 2003; Guettler et al., 2008). MRTFs
are sequestered in the cytoplasm by G-actin and maintained
transcriptionally inactive. The development of mechanical
tension in the fibroblast, along with TGF-b1, promotes F-actin
assembly (Tomasek et al., 2002; Hinz, 2010), causing nuclear
translocation of MRTF-A in a Rho-Rho-kinase (ROCK)-
dependent manner (Miralles et al., 2003; Small et al.,
2010). This leads to activation of the MRTF/SRF complex
and the expression of SMaA and/or the other smooth muscle-
specific cytoskeletal proteins (Mack et al., 2000). It was
recently demonstrated that MRTF-B had a key role in TGF-b1-
induced epithelial–myofibroblast transition (Masszi et al.,
2010), although there has been no study, to our knowledge,
directly demonstrating the role of the MRTFs in myofibroblast
differentiation, in response to TGF-b1.
We hypothesize that the MRTFs are critical in promoting
the expression of a contractile gene program required for
myofibroblast differentiation in response to TGF-b1. There
are a number of smooth muscle-specific cytoskeletal proteins
containing CArG box elements in the promoter regions of
their genes, in addition to SMaA, that are regulated by SRF
and constitute a so-called ‘‘CArGome’’ (Sun et al., 2006). A
subset of these genes is expressed in myofibroblasts in
response to TGF-b1, including SMaA, smooth muscle g-actin
(SMgA), SM22-a, h1-calponin, profilin, and cofilin, suggest-
ing that they are regulated by the MRTFs (Chambers et al.,
2003; Malmstrom et al., 2004). The expression of these genes
in myofibroblasts is important because SMaA-null mice are
able to heal wounds similar to wild-type mice, and isolated
SMaA-null fibroblasts can differentiate into myofibroblasts in
response to TGF-b1 (unpublished observations). These data
suggest that the other CArG-containing smooth muscle-
specific cytoskeletal proteins could be compensating for the
lack of SMaA. Our goal was to evaluate the role of MRTFs as
key regulators of the contractile gene program that mediates
the acquisition of the contractile myofibroblast phenotype in
response to TGF-b1 treatment. We demonstrate that TGF-b1
promotes the expression of a subset of CArG-containing
smooth muscle-specific cytoskeletal proteins in myofibro-
blasts. We show that MRTF-A is sufficient for the expression
of the smooth muscle-specific cytoskeletal proteins and for
the contractile function of the myofibroblast in the absence
of TGF-b1. Conversely, the knockdown of the MRTFs in
TGF-b1-differentiated myofibroblasts is sufficient to diminish
expression of the smooth muscle-specific cytoskeletal pro-
teins and their contractile function. These data demonstrate
that the MRTFs are necessary and sufficient for the
myofibroblast differentiation that occurs in response to
TGF-b1, and that the MRTFs are key regulators of this
contractile gene program.
RESULTS
TGF-b1 increases expression of CArG-containing smooth
muscle-specific cytoskeletal proteins in myofibroblasts
We first explored the possibility that differentiated myofibro-
blasts express a contractile gene program comprised of
smooth muscle-specific cytoskeletal proteins, other than
SMaA, required for their contractile phenotype and function.
Rat embryonic fibroblasts (REF-52) were cultured with
TGF-b1, for 96 hours, to differentiate them into myofibro-
blasts. Using real-time PCR, myofibroblasts were found to
significantly increase their expression of SMaA, SMgA, SM22-
a, h1-calponin, and vinculin (Figure 1a). An increase in the
protein levels of these smooth muscle-specific cytoskeletal
proteins, in response to TGF-b1 treatment, was also demon-
strated through western blot analysis (Figure 1b). Whereas
there was a significant increase in the message levels of
SM22-a and vinculin in REF-52 cells treated with TGF-b1,
there was only a slight increase in these proteins on the
protein level (Figure 1a–b). We were not able to assess the
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Figure 1. Transforming growth factor b-1(TGF-b1) treatment is sufficient for
increased expression of smooth muscle-specific cytoskeletal proteins.
(a) REF-52 cells were plated in supplemented DMEM and stimulated with
0.25 ngml1 TGF-b1 for 96 hours. Total RNA was collected and analyzed for
levels of smooth muscle-specific cytoskeletal protein gene expression by real-
time PCR analysis. mRNA levels are relative to the non-stimulated control
expression levels. Error bars represent mean±average absolute deviation
(AAD), **Po0.01, *Po0.05, or NS (not significant) by Student’s t-test; n¼ 3.
(b) Representative western blot. Total protein was extracted from REF-52 cells,
after 96 hours of TGF-b1 treatment, and analyzed using the indicated
antibodies. The quantification of each protein level is shown relative to
control levels and normalized to b-tubulin. Error bars represent mean±AAD.
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MRTF, myocardin-
related transcription factor; SMaA, smooth muscle a-actin; SMgA, smooth
muscle g-actin.
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SMgA protein levels, as there is no specific antibody currently
available. Despite this, these results confirm that TGF-b1
induces a contractile gene program that includes multiple
contractile proteins, in addition to SMaA, that may contribute
to myofibroblast differentiation.
MRTF-A is sufficient for increased expression of
myofibroblast-specific genes and protein expression in the
absence of TGF-b1
MRTF-A is a SRF co-activator, and stimulates the expression
of a number of cytoskeletal genes (Cen et al., 2003, 2004;
Selvaraj and Prywes, 2004; Morita et al., 2007b). To assess
the ability of MRTF-A to induce myofibroblast differentiation,
we transiently transfected REF-52 cells with a FLAG-tagged,
constitutively active form of MRTF-A (CA-MRTF-A), in the
absence of TGF-b1. Despite the lack of TGF-b1, CA-MRTF-A
stimulated a significant increase in the message levels of
SMaA, SMgA, SM22-a, h1-calponin, and vinculin (Figure 2a).
Increased expression of these smooth muscle-specific cytos-
keletal proteins on the protein level was confirmed by
western blot analysis (Figure 2b). SM22-a and vinculin
message and protein levels were affected the least by the
overexpression of MRTF-A, which was not surprising, as these
proteins were the least upregulated by treatment with TGF-b1
alone (Figure 1). We determined the exogenous protein levels
of MRTF-A expression by using an anti-FLAG antibody. These
data confirm that MRTF-A is sufficient for upregulation
of smooth muscle-specific cytoskeletal proteins found in
myofibroblasts.
Knockdown of MRTF-A/B results in reduced myofibroblast
gene and protein expression
We next evaluated the effect of MRTF knockdown on TGF-
b1-promoted myofibroblast differentiation. It has been
previously reported that MRTFs could potentially compensate
for each other (Cen et al., 2003; Morita et al., 2007b). To
confirm this possibility in our model, we evaluated the
expression levels of the smooth muscle-specific cytoskeletal
proteins in response to MRTF-A or MRTF-B small interfering
RNA (siRNA) alone (Supplementary Figure S1 online). We
found the most robust reduction in expression of the smooth
muscle-specific cytoskeletal proteins by targeting both MRTF-
A and MRTF-B for knockdown with siRNA. Therefore, for the
rest of our studies, REF-52 cells were stimulated with TGF-b1
for 72 hours to promote the myofibroblast phenotype
(Vaughan et al., 2000), then transiently transfected with
MRTF-A/B siRNA or non-targeting siRNA. MRTF-A/B knock-
down had the greatest effect on h1-calponin expression,
reducing its message levels by B80% compared with the
non-targeting siRNA. Similarly, a reduction was observed in
the expression of the other smooth muscle-specific cytoske-
letal proteins, including, SMaA, SMgA, and SM22-a (Figure
3a). Vinculin was least affected by the MRTF-A/B knock-
down, with a reduction of B30% compared with the non-
targeting siRNA. Changes in message levels were shown to
correlate with changes in protein expression (Figure 3b).
To confirm the role of MRTF-A, we transiently transfected
TGF-b1-induced myofibroblasts with MRTF-A/B siRNA or
non-targeting siRNA, plus the CA-MRTF-A construct or an
empty vector control along with an SMaA promoter driving a
firefly luciferase reporter construct and a Renilla luciferase
construct for normalization. Luciferase expression evaluated
48 hours after transfection revealed an almost complete
rescue of SMaA promoter activity in cells treated with
CA-MRTF-A after knockdown with MRTF-A/B siRNA
(Figure 3c). These results indicate that overexpressing
CA-MRTF-A plasmid is able to reverse the effects of the
MRTF-A/B knockdown.
Knockdown of MRTF-A/B results in reduced myofibroblast
phenotype
Differentiated myofibroblasts acquire distinct phenotypic
characteristics including the development of supermature
focal adhesions (Dugina et al., 2001; Goffin et al., 2006). To
determine whether the knockdown of MRTF-A/B had an
effect on the myofibroblast phenotype, TGF-b1-induced
myofibroblasts were transfected with MRTF-A/B siRNA or a
non-targeting siRNA control. After 72 hours, cells were fixed
and stained with an anti-vinculin antibody to visualize focal
adhesions. We found that the size and number of focal
adhesions was significantly reduced in the MRTF-A/B knock-
down cells compared with the control cells (Figure 4a); the
number of supermature focal adhesions above 6 mm2 was
reduced by B50%, with a complete loss of focal adhesions
above 12 mm2 (Figure 4b). This reduction in the size of focal
adhesions is most likely due to decreased generation of
contractile force (see results below), which is consistent with
the mechanosensitive role proposed for focal adhesions
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Figure 2. Myocardin-related transcription factor (MRTF)-A is sufficient for
myofibroblast formation in REF-52 cells independent of TGF-b1 treatment.
(a) REF-52 cells were cultured in supplemented DMEM for 24 hours and
then transfected with FLAG-tagged-CA-MRTF-A or empty vector control for
48 hours. Total RNA was extracted and analyzed for expression of smooth
muscle-specific cytoskeletal proteins using real-time PCR. mRNA levels
are relative to the TIMP2 empty vector control message levels. Error bars
represent mean±average absolute deviation (AAD), ***Po0.001, **Po0.01,
*Po0.05, or NS (not significant) by Student’s t-test; n¼ 3–7. (b) Representative
western blot. Total protein was extracted from REF-52 cells after the treatment
described above, and analyzed using the indicated antibodies. The quantification
of each protein level is shown relative to control levels and normalized to
b-tubulin. Error bars represent mean±AAD. SMaA, smooth muscle a-actin;
SMgA, smooth muscle g-actin; TIMP2, tissue inhibitor of metalloproteinase 2.
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(Grashoff et al., 2010). Our results indicate that the
myofibroblast phenotype can be diminished when the levels
of MRTF-A/B have been reduced.
MRTF-A/B expression contributes to myofibroblast
contractile function
We next evaluated whether MRTF-A/B expression is neces-
sary or sufficient to generate contractile force by using
deformable substrates to measure contractile force generation
(Hinz et al., 2002). To determine whether MRTFs are
necessary for myofibroblast contraction, TGF-b1-induced
myofibroblasts were seeded onto a deformable silicone
substrate in the continuous presence of TGF-b1. We
transiently transfected the cells with either an MRTF-A/B
siRNA or the non-targeting siRNA, and then evaluated the
cells for the presence of wrinkles after 72 hours. We found
that the cells transfected with MRTF-A/B siRNA had a
significantly fewer wrinkles compared with the cells trans-
fected with the non-targeting siRNA control (Figure 4c–d).
These results demonstrate that reducing the levels of MRTF-A/B
in myofibroblasts results in a reduction in their ability to
generate contractile force. To determine whether MRTF-A is
sufficient to increase contractile force generation, we made
use of the same wrinkling assay described above. For these
experiments, REF-52 cells were cultured on a deformable
silicone substrate with stiffness such that the non-treated
fibroblasts would be incapable of wrinkling the substrate. We
transfected the fibroblasts with the CA-MRTF-A and cultured
them for 72 hours. CA-MRTF-A-transfected cells were able to
generate significantly more wrinkles than the cells transfected
with the empty vector control (Figure 4e). Taken together,
these data suggest that the MRTFs induce the expression of
contractile proteins that have an important role in promoting
the contractile ability of the myofibroblast.
DISCUSSION
It is well established that myofibroblasts are present in the
granulation tissue of wounds in both normal and pathological
situations (Gabbiani et al., 1971; Ryan et al., 1974; Gabbiani,
1979, 2003; Serini and Gabbiani, 1999; Desmouliere et al.,
2003). TGF-b1 is a key mediator of myofibroblast formation
and has been shown to have a role in their differentiation in
wound healing and tissue contractures (Border and Ruoslahti,
1992; Serini and Gabbiani, 1999; Tomasek et al., 2002,
2005); however, it remains unclear how myofibroblasts
differentiate from fibroblasts and attain their characteristic
contractile phenotype in response to TGF-b1. In this study,
we examined the role of MRTF-A/B as the key regulators of
the myofibroblast differentiation that occurs in response to
TGF-b1. We show that TGF-b1 induces increased expression
of not only SMaA, the widely accepted hallmark of the
myofibroblast, but also other CArG-containing genes such as
SMgA, SM22-a, h1-calponin, and vinculin in REF-52 cells.
Knockdown of MRTF-A/B reverses TGF-b1-enhanced expres-
sion of these smooth muscle-specific cytoskeletal proteins
and a correlated loss of supermature focal adhesions and
reduction in contractile force generation. These results
suggest the presence of a contractile program, consisting of
CArG-containing genes regulated by MRTF-A/B, which are
required for TGF-b1-promoted myofibroblast formation and
function.
Our findings are consistent with the model that MRTFs
have a key role in regulating TGF-b1-promoted myofibroblast
differentiation. Expression of CA-MRTF-A was sufficient to
promote myofibroblast formation and function in the absence
of TGF-b1; furthermore, knockdown of MRTF-A/B could
reverse TGF-b1 promoted myofibroblast formation and
function. Previous studies have demonstrated that either
knocking down MRTFs or using dominant-negative MRTF-A
can reduce the expression of SMaA and other contractile
proteins, as well as reduce focal adhesions and stress fibers
(Morita et al., 2007b; Chan et al., 2010). However, these
other studies used NIH3T3 fibroblasts that were not
differentiated into myofibroblasts with TGF-b1. Fibroblasts
cultured on a non-compliant substratum in the presence of
fetal bovine serum can form stress fibers and focal adhesions
and express low levels of SMaA, referred to as protomyofi-
broblasts (Tomasek et al., 2002); TGF-b1 is required for
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Figure 3. Myocardin-related transcription factor (MRTF)-A/B knockdown
reduces smooth muscle-specific cytoskeletal protein expression in
myofibroblasts. (a) Transforming growth factor b-1-induced myofibroblasts
were transfected with MRTF-A/B or non-targeting (NT) small interfering RNA
(siRNA) for 48 hours. mRNA levels were analyzed by real-time PCR and
normalized to NT siRNA; n¼ 5. (b) Representative western blot. Total protein
was extracted from REF-52 cells after treatment described above and analyzed
using the indicated antibodies. Quantification of protein level is shown
relative to control level and normalized to b-tubulin. (c) Myofibroblasts were
co-transfected with MRTF-A/B siRNA or NT siRNA, constitutively active
MRTF (CA-MRTF)-A or empty vector control, plus a smooth muscle a-actin
(SMaA) promoter expressing luciferase and a Renilla luciferase control, and
then evaluated at 48hours post transfection for luciferase expression; n¼ 3.
Error bars represent mean±average absolute deviation, ***Po0.001,
**Po0.01, *Po0.05, or NS (not significant) by Student’s t-test.
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the formation of the fully differentiated myofibroblast
characterized by supermature focal adhesions, large stress
fibers, enhanced generation of contractile force, and strong
expression of SMaA both in vitro and in vivo (Desmouliere
et al., 1993; Dugina et al., 2001; Tomasek et al., 2002). The
significance of our study is the demonstration that knocking
down MRTF-A/B can completely reverse all of the myofibro-
blast characteristics that occur in response to TGF-b1. Recently,
Small and co-workers demonstrated, using a MRTF-A-null
mouse, that lack of MRTF-A results in reduced myofibroblast
activation and fibrosis in response to myocardial infarction
(Small et al., 2010). Taken together, these studies implicate
MRTFs as critical for myofibroblast formation and function.
The formation of supermature focal adhesions and
increased generation of contractile force in the TGF-b1-
differentiated myofibroblast is most likely the result of
increased expression of smooth muscle-specific cytoskeletal
proteins in response to increased transcriptional activation of
MRTFs. Overexpression of SMaA promotes formation of
supermature focal adhesions and increased contractile force
generation (Hinz et al., 2001), whereas a role for SM22-a and
h1-calponin in promoting myofibroblast formation and
function is consistent with their proposed role of promoting
actin assembly and increased force generation in vascular
smooth muscle cells (Wu and Jin, 2008; Han et al., 2009).
Consistent with these results, reducing contractile force
generation by reducing myosin II activity with blebbistatin
results in loss of supermature focal adhesions (Goffin et al.,
2006). The expression of SMaA, while a marker for
myofibroblasts, does not appear to be essential for myofibro-
blast formation and function. Recent studies from our lab
have found that SMaA-null mice exhibit normal wound
healing and myofibroblast formation and function, suggesting
compensation by other smooth muscle contractile proteins
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Figure 4. Myocardin-related transcription factors (MRTFs) contribute to myofibroblast morphology and contractile function. (a) Transforming growth
factor b-1-induced myofibroblasts were transfected with MRTF-A/B small interfering RNAs (siRNAs) or non-targeting (NT) siRNA, and then stained with an
anti-vinculin antibody at 72 hours post transfection; bar¼ 40 mm. (b) Focal adhesion quantification was performed for 10 cells per treatment. (c) Myofibroblasts
were seeded on a deformable substrate (5 kPa stiffness) and transfected with MRTF-A/B siRNAs or NT siRNA for 72 hours. Bar¼ 40mm. White arrows point to
examples of wrinkles. (d) Quantification of percent cells wrinkling substrate after treatment with MRTF-A/B siRNA or NT siRNA. (e) Quantification of percent cells
wrinkling the substrate after transfection with FLAG-tagged-constitutively active MRTF (CA-MRTF)-A, compared with empty vector, after 72hours. Error bars
represent mean±SEM., ***Po0.001, **Po0.01, or *Po0.05 by Student’s t-test; n¼ 3.
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(Tomasek JJ, unpublished observations). The disassembly of
SMaA from stress fibers of myofibroblasts, using an NH2-
terminal peptide of SMaA, results in the loss of supermature
focal adhesions and force generation (Dugina et al., 2001;
Hinz et al., 2002); however, this NH2-terminal peptide
appears to alter actin dynamics throughout the cell (Clement
et al., 2005), and may have the global effect of reducing stress
fiber assembly and force generation that does not occur with
just the loss of SMaA. These studies stress the importance of
the expression of smooth muscle-specific cytoskeletal pro-
teins and their regulation by MRTFs during myofibroblast
differentiation.
The mechanism by which TGF-b1 promotes MRTF-A/B
activation is currently unclear. MRTF-A/B activity is regulated
by actin dynamics (Sotiropoulos et al., 1999; Miralles et al.,
2003). Stimulation of the Rho/ROCK signaling cascade
promotes actin assembly with resulting nuclear translocation
of MRTFs and expression of smooth muscle contractile
proteins (Miralles et al., 2003; Zhao et al., 2007; Guettler
et al., 2008). TGF-b1 can activate the Rho/ROCK pathway
(Harvey et al., 2007; Meckmongkol et al., 2007), and it has
recently been demonstrated that TGF-b1 can promote
nuclear translocation of MRTF-A in a ROCK-dependent
manner in cardiac fibroblasts (Small et al., 2010). We have
found that the ROCK inhibitor Y27632 will inhibit TGF-b1-
promoted myofibroblast differentiation in REF-52 fibroblasts,
and that CA-MRTF-A can reverse this inhibition (Supplemen-
tary Figure S2 online). These results suggest that TGF-b1 may
activate MRTFs through the Rho/ROCK pathway. However,
TGF-b1 can also activate the well-characterized Smad
signaling pathway that can promote expression of SMaA
and SM22-a (Subramanian et al., 2004; Walker et al., 2004).
In addition, it has recently been reported in epithelial–myofi-
broblast transition that Smad3 binds to MRTF-B, blocking
MRTF/SRF interaction, and that TGF-b1 will release this
inhibition, promoting MRTF/SRF complex formation and
activation of MRTF (Masszi et al., 2010). Further studies will
be needed to understand the complex relationship between
TGF-b1 signaling and MRTF activation that promotes
myofibroblast differentiation.
We have shown through multiple approaches that TGF-b1
promotes myofibroblast differentiation through the activity of
the MRTFs. On the basis of our findings, we propose a model
of TGF-b1-induced fibroblast to myofibroblast differentiation
(Figure 5). In this model, exposure of the fibroblast to TGF-b1
will induce the MRTFs to translocate into the nucleus, bind to
SRF, and promote expression of a contractile gene program,
consisting of CArG-containing genes such as SMaA, SMgA,
SM22-a, h1-calponin, and vinculin. The expression of these
genes induces the assembly of a contractile cytoskeleton,
resulting in a positive feedback loop of MRTF activity and
smooth muscle-specific cytoskeletal protein expression,
ultimately promoting the differentiation of the myofibroblast
and its contractile function. Further studies investigating the
group action of smooth muscle-specific cytoskeletal proteins
in the contractile phenotype may provide new insight into the
formation and function of the myofibroblast and the potential
generation of future therapies for pathological contractures.
MATERIALS AND METHODS
Cell culture
Rat embryonic fibroblasts (REF-52) were obtained as a generous gift
from Dr Boris Hinz (University of Toronto, Toronto, Canada). The cells
were cultured in supplemented DMEM (Invitrogen, Carlsbad, CA), plus
10% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA),
1% sodium pyruvate (Sigma-Aldrich, St Louis, MO), and 1% antibiotic/
antimycotic (Sigma-Aldrich). Myofibroblasts were generated by stimu-
lating REF-52 cells in supplemented DMEM with 0.25ngml1 TGF-b1
(Peprotech, Rocky Hill, NJ; Vaughan et al., 2000). All experiments were
performed with cells between 40 and 50 passages.
Constructs
A FLAG-tagged CA-MRTF-A was constructed by removing the first
89 amino acids, which abrogates the ability of MRTF-A to interact
with G-actin (Morita et al., 2007a). The empty vector, pCDF-MCS2-
EF1-cop-GFP (System Biosciences, Mountain View, CA), was used as
a control. The SMaA reporter construct was made by amplifying a
mouse SMaA promoter (Mack et al., 2000) and cloning it into pGL3-
Basic (System Biosciences). Further details can be found in
Supplementary Material online.
CA-MRTF-A or empty vector transfections
REF-52 cells were transiently transfected using Lipofectamine/Plus
Reagent (Invitrogen). The culture medium was changed approxi-
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Figure 5. Proposed model of myofibroblast differentiation from fibroblasts
in response to TGF-b1. The fibroblast when exposed to TGF-b1 increases
assembly of F-actin inducing the myocardin-related transcription factor
(MRTF)-A/B to translocate into the nucleus, bind to serum response factor
(SRF), and promote expression of a contractile gene program, consisting
of CArG-containing genes such as smooth muscle a-actin (SMaA), SMgA,
SM22-a, h1-calponin, and vinculin. The expression of these genes causes
changes to the cytoskeleton, resulting in a positive feedback loop of MRTF
activity and smooth muscle-specific cytoskeletal protein (SMCP) gene expression,
and ultimately, the differentiation of the myofibroblast and the development
of contractile function (figure modified from Tomasek et al., 2002).
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mately 16 hours after transfection and evaluated at 48 hours post
transfection by real-time PCR and western blot analysis, and
72 hours by the wrinkling assay analysis.
siRNA
For smooth muscle-specific cytoskeletal protein expression analysis
and for contraction analysis myofibroblasts were transiently trans-
fected with 120nM total On-Target Plus siRNA pools specific for
MRTF-A and MRTF-B or a control non-targeting siRNA pool
(Dharmacon, Lafayette, CO), using Dharmafect 2 (Dharmacon)
transfection reagent. For the focal adhesion analysis, myofibroblasts
were transiently transfected with 60nM total siRNA using Lipofect-
amine 2000 (Invitrogen) transfection reagent. siRNA target sequences
and other details are reported in Supplementary Material online.
KD and rescue
Myofibroblasts were transiently transfected with 120 nM total On-
Target Plus siRNA pools specific for MRTF-A and MRTF-B or a
control non-targeting siRNA pool (Dharmacon), a SMaA promoter–-
reporter construct expressing luciferase or a empty vector, and
phosphotyrosine kinase promoter–reporter construct expressing
Renilla firefly (Promega Corp, Madison, WI) as a normalization
control. Lipofectamine 2000 (Invitrogen) transfection reagent was
used for the transfections. The luciferase expression was analyzed
48 hours post transfection.
Real-time reverse transcription-PCR
Total RNA was extracted from REF-52 cells using Trizol Reagent
(Invitrogen) according to the manufacturer’s protocol. Primer sequences
and other details are reported in Supplementary Material online.
Immunocytochemistry for focal adhesions
Myofibroblasts were seeded onto glass coverslips at B30%
confluence, transfected with MRTF-A and MRTF-B siRNA
pools, and maintained in 0.25 ngml1. TGF-b1 (Peprotech) for
72 hours. Cells were then per-fixed (Smith-Clerc and Hinz, 2010),
incubated with an anti-vinculin antibody (Sigma-Aldrich), followed
by the appropriate secondary antibody conjugated to AlexaFluor 488
(Molecular Probes, Eugene, OR). Images of 10 cells per treatment
were analyzed for focal adhesion size and number using Image Pro
Plus Quantification Software (Media Cybernetics, Bethesda, MD).
Western blot analysis
Whole cell lysates were collected in 1% SDS lysis buffer and total
protein was quantified using the Pierce BCA Protein Assay Kit
(Thermo Scientific, Rockford, IL). Samples were adjusted to equal
protein concentration and separated by electrophoresis on an SDS
gel. The separated proteins were then transferred onto a poly-
vinylidene difluoride membrane (Pall Corporation, Pensacola, FL)
and incubated with the appropriate antibodies. Details about
antibodies can be found in Supplementary Material online. Blots
were developed with Immun-Star chemiluminescence substrate
(Bio-Rad, Hercules, CA). X-ray film (X-OMAT AR5; Kodak,
Rochester, NY) was exposed to the chemiluminscence reaction
and developed. The CA-MRTF-A transfection experiments were
analyzed at 48 hours post transfection and the siRNA studies were
conducted at 72 hours post transfection.
Contraction assay
The ability of cells to wrinkle a deformable substrate correlates with
contractile force generation (Hinz et al., 2001). Deformable
substrates were prepared for cell seeding by first etching the plate
with 30% sulfuric acid for 10minutes, rinsing profusely with sterile
water, and then coating the surface with Type 1 Rat Tail Collagen
(5mgml1; Millipore, Temecula, CA) for 1 hour. For CA-MRTF-A
contraction analysis, REF-52 cells were seeded on deformable
substrates (45o10 kilopascals stiffness; ExCellness Biotech,
Lausanne, Switzerland) in the absence of TGF-b1, transfected with
either the CA-MRTF-A vector or empty vector, cultured for 72 hours,
and then fixed with 4% paraformaldehyde. FLAG-tagged-CA-
MRTF-A transfected cells were identified by staining with an
anti-FLAG antibody (Sigma-Aldrich) and Alexa Fluor 546 (Invitro-
gen) secondary antibody. Empty vector-transfected cells were
identified by expression of GFP. Cultures were stained with DAPI
Nuclear Stain (Molecular Probes) to identify all cells. Cultures
were analyzed by epifluorescence and phase microscopy to
determine the percentage of CA-MRTF-A and empty vector-
transfected cells that wrinkled the substratum. For siRNA contraction
analysis, myofibroblasts were seeded on deformable substrates
(5 kPa stiffness; ExCellness Biotech), transiently transfected with
siRNA pools as described above, and cultured for 72 hours.
To determine percent cells wrinkling the substrate, live cells were
stained with Hoechst 33342 (Molecular Probes; 0.2 mgml1) to stain
nuclei and examined live by epifluorescence and phase microscopy.
Further details can be found in Supplemental Material online.
Statistical analysis
Results were analyzed by the paired, one-tailed Student’s t-test. Error
bars were calculated as either average absolute deviation (AAD) or
as SEM as noted in the figure legend. Differences were considered
to be statistically significant at values of Pp0.05; P values are as
indicated by asterisks: ***Po0.001, **Po0.01, *Po0.05.
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